Novartis OTC Stock Today

NVSEF -  USA Stock  

USD 85.40  1.60  1.84%

Market Performance
2 of 100
Odds Of Distress
Less than 17
Novartis is trading at 85.40 as of the 21st of May 2022, a -1.84% down since the beginning of the trading day. The stock's lowest day price was 85.4. Novartis has less than a 17 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Novartis Ag Basl are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 21st of April 2022 and ending today, the 21st of May 2022. Click here to learn more.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. The company has 2.24 B outstanding shares. More on Novartis Ag Basl
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Novartis OTC Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Novartis' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Novartis or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Latest headline from Lytix Biopharma - Invitation to Capital Markets Day in Oslo, June 1, 2022 -
President CEOChris Ilsley  (View All)
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Novartis' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong HoldFairly Valued
Novartis Ag Basl [NVSEF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Mega-Cap' category with current market capitalization of 194.95 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novartis's market, we take the total number of its shares issued and multiply it by Novartis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Novartis Ag Basl classifies itself under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 2.24 B outstanding shares. Novartis Ag Basl has accumulated about 18.72 B in cash with 14.59 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.46.
Check Novartis Probability Of Bankruptcy
Novartis Ag Basl holds a total of 2.24 Billion outstanding shares. 30% of Novartis outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.

Ownership Allocation (%)

Check Novartis Ownership Details

Novartis Stock Price Odds Analysis

What are Novartis' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Novartis jumping above the current price in 90 days from now is about 58.84%. The Novartis Ag Basl probability density function shows the probability of Novartis otc stock to fall within a particular range of prices over 90 days. Assuming the 90 days horizon Novartis Ag Basl has a beta of close to zero. This indicates the returns on DOW and Novartis do not appear to be highly-sensitive. Additionally, it does not look like the company alpha can have any bearing on the current equity valuation.
  Odds Below 85.4HorizonTargetOdds Above 85.4
40.88%90 days
Based on a normal probability distribution, the odds of Novartis to move above the current price in 90 days from now is about 58.84 (This Novartis Ag Basl probability density function shows the probability of Novartis OTC Stock to fall within a particular range of prices over 90 days) .

Novartis Ag Basl Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Novartis market risk premium is the additional return an investor will receive from holding Novartis long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Novartis. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Novartis' alpha and beta are two of the key measurements used to evaluate Novartis' performance over the market, the standard measures of volatility play an important role as well.

Novartis Stock Against Markets

Picking the right benchmark for Novartis otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Novartis otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Novartis is critical whether you are bullish or bearish towards Novartis Ag Basl at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Novartis without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Transaction History Now


Transaction History

View history of all your transactions and understand their impact on performance
All  Next Launch Module

Novartis Corporate Directors

Novartis corporate directors refer to members of a Novartis board of directors. The board of directors generally takes responsibility for the Novartis' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Novartis' board members must vote for the resolution. The Novartis board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Ton Buechner - Non-Executive Independent DirectorProfile
Pierre Landolt - Member of the Board of DirectorsProfile
Elizabeth Doherty - Non-Executive Independent DirectorProfile
Srikant Datar - Member of the Board of DirectorsProfile

Investing Novartis Ag Basl

You need to understand the risk of investing before taking a position in Novartis. The danger of trading Novartis Ag Basl is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Novartis is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Novartis. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Novartis Ag Basl is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additionally, see Stocks Correlation. Note that the Novartis Ag Basl information on this page should be used as a complementary analysis to other Novartis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for Novartis OTC Stock analysis

When running Novartis Ag Basl price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Novartis Ag Basl is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine Novartis value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.